XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Xenetic Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.93−0.06 (-3.02%)
Close on Oct 19, 2026
- Market cap
- $4.43M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
6.5%
0M of 2M shares
Institutional holders
8
2 new, 0 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Dmitry Genkin | 215,964 | – | 13D (active) amendment | Mar 18, 2024 |
| Renaissance Technologies LLC | 137,440 | 6.00% | 13G (passive) amendment | Mar 31, 2026 |
| Michael Liu | 126,741 | 5.50% | 13G (passive) | May 22, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of XBIO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Renaissance Technologies LLC | 117,440 | 5.01% | $341.75K | −20,000 | 0.00% |
| Geode Capital Management, LLC | 17,423 | 0.74% | $50.72K | −4,018 | 0.00% |
| Vanguard Capital Management LLC | 12,681 | 0.54% | $36.90K | +5,950 | 0.00% |
| JTC Employer Solutions Trustee Ltd | 2,700 | 0.12% | $8 | – | 0.00% |
| SBI Securities Co., Ltd. | 1,000 | 0.04% | $2.91K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 696 | 0.03% | $2.03K | −110 | 0.00% |
| Morgan Stanley | 150 | 0.01% | $437 | New | 0.00% |
| Darwin Wealth Management, LLC | 2 | 0.00% | $5 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 8 | 0M | 6.5% | 2 / 1 | 3 / 0 | 0M | 0M |
| Q1 2026 | 6 | 0M | 7.2% | 1 / 1 | 2 / 6 | 0M | 0M |
| Q4 2025 | 11 | 0M | 9.8% | 4 / 3 | 1 / 3 | 0M | 0M |
| Q3 2025 | 10 | 0M | 2.5% | 2 / 2 | 1 / 1 | 0M | 0M |
| Q2 2025 | 9 | 0M | 2.7% | 0 / 2 | 2 / 4 | 0M | 0M |
| Q1 2025 | 13 | 0M | 4.6% | 1 / 6 | 1 / 1 | 0M | 0M |
| Q4 2024 | 13 | 0M | 3.8% | 6 / 1 | 2 / 2 | 0M | 0M |
| Q3 2024 | 9 | 0M | 2.1% | 5 / 1 | 1 / 1 | 0M | 0M |
| Q2 2024 | 5 | 0M | 0.6% | 1 / 1 | 2 / 3 | 0M | 0M |
| Q1 2024 | 7 | 0M | 0.8% | 0 / 2 | 1 / 0 | 0M | 0M |
| Q4 2023 | 7 | 0M | 0.7% | 1 / 1 | 2 / 1 | 0M | 0M |
| Q3 2023 | 7 | 0M | 0.7% | 1 / 1 | 2 / 3 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of XBIO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 13,725 | 0.59% | $42.82K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 12,681 | 0.54% | $36.90K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 2,070 | 0.09% | $6.46K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 1,388 | 0.06% | $4.33K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| James F. Parslow | Interim CEO and CFO | 100,000 | 4.27% | Apr 23, 2026 |
| Roger D. Kornberg | Director | 0 | – | Jan 5, 2026 |
| Firdaus J. Dastoor | Director | – | – | Jan 5, 2026 |
| Grigory G. Borisenko | Director | – | – | Jan 5, 2026 |
| Alexey Andreevich Vinogradov | Director | 186,781 | 7.97% | Jan 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| James F. Parslow Interim CEO and CFO | Apr 21, 2026 | Award | +100,000 | – | – | 100,000 |
| Dmitry Genkin Director | Jul 19, 2019 | Award | +93,390 | – | – | 93,603 |
| Dmitry Genkin Director | Mar 14, 2018 | Other | −29,452 | – | – | 2,549 |
| Jeffrey F. Eisenberg CEO, Director | Oct 26, 2017 | Award | +50,000 | – | – | 50,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.